MedTrace Logo

Xarelto for VTE Prophylaxis After Hip or Knee Arthroplasty

NCT00831714 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 19076

Last updated 2017-01-23

No results posted yet for this study

Summary

The main goal is to provide additional information to the risk-benefit assessment of the drug.

Conditions

  • Venous Thromboembolism

Interventions

DRUG

Rivaroxaban (Xarelto, BAY59-7939)

Female and male patients, who are at least 18 years of age and will undergo elective hip or knee arthroplasty, after the decision for VTE prophylaxis with Rivaroxaban has been made

DRUG

Standard care treatment for VTE prophylaxis

Female and male patients, who are at least 18 years of age and will undergo elective hip or knee arthroplasty, after the decision for a pharmacologic VTE prophylaxis treatment other than rivaroxaban has been made

Sponsors & Collaborators

  • Janssen Research & Development, LLC

    collaborator INDUSTRY

  • Bayer

    lead INDUSTRY

Principal Investigators

  • Bayer Study Director · Bayer

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-02-28
Primary Completion
2011-06-30
Completion
2013-04-30

Countries

  • Australia
  • Austria
  • Belgium
  • Bosnia and Herzegovina
  • Brazil
  • Canada
  • Chile
  • China
  • Colombia
  • Cyprus
  • Czechia
  • Denmark
  • Estonia
  • Finland
  • France
  • Germany
  • Greece
  • Hong Kong
  • Hungary
  • India
  • Italy
  • Latvia
  • Lebanon
  • Lithuania
  • Mexico
  • Netherlands
  • North Macedonia
  • Norway
  • Philippines
  • Portugal
  • Serbia
  • Singapore
  • Slovakia
  • South Africa
  • South Korea
  • Spain
  • Sweden
  • Switzerland
  • United Arab Emirates
  • United Kingdom
  • Venezuela
  • Vietnam

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00831714 on ClinicalTrials.gov